1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shares in COVID-19 vaccine developer Valneva extend fall

01/05/2022 | 05:05am EDT
Biotech firm Valneva works on an inactivated whole-virus vaccine against COVID-19 in Vienna

PARIS (Reuters) - Shares in biotech company Valneva fell again on Wednesday, declining for the seventh day in a row due to a growing belief amongst investors that the COVID-19 Omicron variant might lessen the need for mass vaccination.

At 0945 GMT, Valneva shares were down 3% at 17.10 euros, meaning the stock has now lost close to 40% since its Dec. 27 close of 26.38 euros.

It did gain more than 200% a year in 2021 and 2020 as Valneva's COVID-19 vaccine candidate came increasingly closer to approval. It is still awaiting a green light for its shot in the European Union and Britain.

"The decline of the share price seems to be mostly driven by retail investors who think that there will be no need of a new vaccination campaign after the Omicron wave", a Paris-based analyst said.

Companies whose COVID-19 vaccines have already been approved have also seen their shares dip since the start of the year, with Pfizer losing 7.65% over the last two days and Moderna down 8.2%.

Initial data in various countries seem to suggest that Omicron -- the most contagious of all the COVID variants to date with new cases at record levels in many countries -- is less likely to send infected people to hospital.

(Reporting by Anait Miridzhanian, Benoit Van Overstraeten; Editing by Emelia Sithole-Matarise)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.40% 10588 Delayed Quote.21.92%
MODERNA, INC. 8.73% 147.66 Delayed Quote.-41.86%
PFIZER, INC. -0.15% 53.91 Delayed Quote.-8.70%
VALNEVA SE 3.16% 11.415 Real-time Quote.-53.41%
All news about ASTRAZENECA PLC
05/27AstraZeneca Doses First Patients in Phase-III Trial Evaluating Anifrolumab in Kidney In..
05/27First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
05/27ASTRAZENECA : Berenberg keeps its Buy rating
05/26Cancer treatments may benefit from lessons of pandemic set-backs -AstraZeneca executive
05/25ASTRAZENECA : JP Morgan keeps its Buy rating
05/25French health body backs new COVID vaccine booster campaign for this autumn
05/24Indian vaccine giant Serum plans African plant in global expansion
05/24Danske Bank Initiates Coverage on AstraZeneca With Buy Rating
05/24Vaxzevria approved in the EU as third dose booster against COVID-19
05/24AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 665 M - -
Net income 2022 5 151 M - -
Net Debt 2022 23 311 M - -
P/E ratio 2022 40,4x
Yield 2022 2,21%
Capitalization 207 B 207 B -
EV / Sales 2022 5,27x
EV / Sales 2023 4,84x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 26
Last Close Price 133,47 $
Average target price 143,66 $
Spread / Average Target 7,64%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC21.92%206 801
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ROCHE HOLDING AG-13.00%281 098